News Column

Findings from Methodist Hospital Research Institute in the Area of Therapeutics Reported (High capacity nanoporous silicon carrier for systemic...

September 11, 2014



Findings from Methodist Hospital Research Institute in the Area of Therapeutics Reported (High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics)

By a News Reporter-Staff News Editor at Women's Health Weekly -- Fresh data on Therapeutics are presented in a new report. According to news reporting out of Houston, Texas, by NewsRx editors, research stated, "Gene silencing agents such as small interfering RNA (siRNA) and microRNA offer the promise to modulate expression of almost every gene for the treatment of human diseases including cancer. However, lack of vehicles for effective systemic delivery to the disease organs has greatly limited their in vivo applications."

Our news journalists obtained a quote from the research from Methodist Hospital Research Institute, "In this study, we developed a high capacity polycation-functionalized nanoporous silicon (PCPS) platform comprised of nanoporous silicon microparticles functionalized with arginine-polyethyleneimine inside the nanopores for effective delivery of gene silencing agents. Incubation of MDA-MB-231 human breast cancer cells with PCPS loaded with STAT3 siRNA (PCPS/STAT3) or GRP78 siRNA (PCPS/GRP78) resulted in 91 and 83% reduction of STAT3 and GRP78 gene expression in vitro. Treatment of cells with a microRNA-18a mimic in PCPS (PCPS/miR-18) knocked down 90% expression of the microRNA-18a target gene ATM. Systemic delivery of PCPS/STAT3 siRNA in murine model of MDA-MB-231 breast cancer enriched particles in tumor tissues and reduced STAT3 expression in cancer cells, causing significant reduction of cancer stem cells in the residual tumor tissue. At the therapeutic dosage, PCPS/STAT3 siRNA did not trigger acute immune response in FVB mice, including changes in serum cytokines, chemokines, and colony-stimulating factors. In addition, weekly dosing of PCPS/STAT3 siRNA for four weeks did not cause signs of subacute toxicity based on changes in body weight, hematology, blood chemistry, and major organ histology."

According to the news editors, the research concluded: "Collectively, the results suggest that we have developed a safe vehicle for effective delivery of gene silencing agents."

For more information on this research see: High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. Acs Nano, 2013;7(11):9867-80. (American Chemical Society - www.acs.org; Acs Nano - www.pubs.acs.org/journal/ancac3)

Our news journalists report that additional information may be obtained by contacting J. Shen, Dept. of Nanomedicine, The Methodist Hospital Research Institute , Houston, Texas 77030, United States. Additional authors for this research include R. Xu, J. Mai, H.C. Kim, X. Guo, G. Qin, Y. Yang, J. Wolfram, C. Mu, X. Xia, J. Gu, X. Liu, Z.W. Mao, M. Ferrari and H. Shen (see also Therapeutics).

Keywords for this news article include: Houston, Texas, United States, North and Central America, Cancer, Oncology, Therapeutics, Therapy.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Women's Health Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters